myNEO leads in Personalised Medicine and genomic-informed drug discovery
in the key therapeutic areas of oncology and immunology.
The ImmunoEngine© is a computational sequencing-based neoepitope selection platform that predicts the most efficacious targets for each individual cancer patient, critical to developing a successful personalized immunotherapy. In parallel, the platform continuously screens public and private databases to discover new immunogenic targets for both untackled cancer indications and new infectious diseases. To increase clinical performance of the platform, data of all patients across biopharma partners are combined into one centralized myNEO network.